Patrick J. Christmas, Chief Strategy and Legal Officer of REGENXBIO Inc., reported the acquisition of 34,722 shares of common stock underlying a time-based restricted stock unit award, with a transaction date of November 1, 2026, in a filing submitted November 3, 2026.

Key Highlights

  • Recipient and role: Patrick J. Christmas, Chief Strategy and Legal Officer of REGENXBIO Inc. (NASDAQ:RGNX)
  • Shares acquired: 34,722 shares of common stock underlying a restricted stock unit award, acquired at $0.00
  • Transaction date: November 1, 2026
  • Vesting schedule: 1/3 of the RSU shares vest on each of November 1, 2027, November 1, 2028, and November 1, 2029, subject to continuous service
  • Post-transaction ownership: 240,690 shares of common stock beneficially owned directly following the reported transaction

REGENXBIO Chief Strategy and Legal Officer Reports RSU Grant in November 2026

According to the filing, Patrick J. Christmas, who serves as Chief Strategy and Legal Officer at REGENXBIO Inc., a gene therapy company based in Rockville, Maryland, reported the acquisition of 34,722 shares of common stock through a restricted stock unit award. The transaction was coded as an acquisition ("A") and carried a price of $0.00, consistent with a grant rather than an open-market purchase. Following the transaction, Christmas directly held 240,690 shares of REGENXBIO common stock.

The filing states that the RSU award vests in equal installments, with one-third of the shares vesting on each of November 1, 2027, November 1, 2028, and November 1, 2029, provided that the recipient maintains continuous service to the issuer through each vesting date. No derivative securities were reported in Table II of the filing. REGENXBIO, which trades on NASDAQ under the symbol RGNX, focuses on gene therapy development using its NAV Technology Platform.

The filing was signed by Patrick J. Christmas on November 3, 2026, and was submitted as an individual filing by one reporting person. No amendment date was indicated, suggesting this was an original filing rather than a correction to a prior submission.

What Was Disclosed

REGENXBIO's Chief Strategy and Legal Officer reported receiving a time-based RSU award covering 34,722 shares on November 1, 2026, vesting in thirds over three years, bringing his direct beneficial ownership to 240,690 shares of common stock.